Histoplasma Capsulatum Antigen Persistence and Rate of Decay During Treatment of Histoplasmosis Varies by Immune Status

Clicks: 1
ID: 327986
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #548 of 550 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 550 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Previous studies examining Histoplasma antigen trends are largely in people living with HIV (PLWH) before the antiretroviral therapy era, with limited generalizability to modern cohorts of histoplasmosis. METHODS: We conducted a single-center, retrospective study of adult patients diagnosed with histoplasmosis by positive antigen testing and undergoing treatment between 2007 to 2021. Mean rates of antigen clearance were estimated using a linear mixed effects model. Time to H. capsulatum antigen negativity was calculated using competing risk analysis. Per-patient, mean antigen levels were compared at time of diagnosis and subsequent 6mo intervals. RESULTS: 83 patients met inclusion criteria: 25 transplant, 21 immunocompetent, 16 biologic therapy, 11 PLWH, and 10 with other immunocompromise (OI). The transplant (-0.07), biologic (-0.07), and OI groups (-0.05) cleared antigenuria significantly slower than PLWH (-0.21) and the immunocompetent group (-0.16). Median time to antigen negativity in the presence of competing risk of death was transplant: 20.3 months (95% CI: 11.6, 69.3), biologic: 14.6 months (9.0, 42.6), OI: 13.2 months (2.0, 82.5), PLWH: 12.9 months (1.9, 19.2), and immunocompetent: 6.8 months (2.8, 13.0). At one year, antigen positivity was more common in immunocompromised than immunocompetent patients (22/40, 55% vs. 3/16, 19%; p = 0.02) and among the immunocompromised groups only transplant, biologic, and OI patients had positivity at two years. CONCLUSIONS: Patients with chronic non-HIV immunosuppression demonstrated persistent antigenuria and cleared antigen more slowly compared to immunocompetent patients and immune reconstituted PLWH. Given the association of antigen persistence with immune status, its clinical significance in non-HIV immunocompromised populations requires evaluation.
Reference Key
openalex_W7210280564 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sara C. Fallon, Julio C Zuniga-Moya, Adriana M. Rauseo, Marcela Araújo de Oliveira Santana, Patrick B Mazi, Andrej Spec
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag533
URL
https://doi.org/10.1093/cid/ciag533
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.